Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort

[1]  A. Vincent-Salomon,et al.  Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort , 2021, npj Breast Cancer.

[2]  G. Siegal,et al.  Receptor conversion in metastatic breast cancer: analysis of 390 cases from a single institution , 2020, Modern Pathology.

[3]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[4]  C. Curtis,et al.  Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases , 2020, Nature Genetics.

[5]  S. Mathoulin-Pélissier,et al.  Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. , 2020, European journal of cancer.

[6]  P. Brown,et al.  Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival. , 2020, Neuro-oncology.

[7]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Sleijfer,et al.  The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies , 2019, Nature Genetics.

[9]  L. Saal,et al.  Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study , 2019, Nature Medicine.

[10]  H. Rugo,et al.  Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer , 2019, The New England journal of medicine.

[11]  F. Bertucci,et al.  Genomic characterization of metastatic breast cancers , 2019, Nature.

[12]  S. Mathoulin-Pélissier,et al.  The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME) , 2019, BMJ Open.

[13]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[14]  A. Ferrari,et al.  Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.

[15]  M. Kerin,et al.  Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER−/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact? , 2018, Pathology & Oncology Research.

[16]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[17]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Fukuma,et al.  Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining , 2018, Breast Cancer.

[19]  P. V. van Diest,et al.  Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.

[20]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[21]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Amy M. Sitapati,et al.  Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[24]  P. Tan,et al.  Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group , 2016, Journal of Clinical Pathology.

[25]  B. Knudsen,et al.  Effects of tissue decalcification on the quantification of breast cancer biomarkers by digital image analysis , 2014, Diagnostic Pathology.

[26]  A. Vincent-Salomon,et al.  [Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]. , 2014, Annales de pathologie.

[27]  A. Goldhirsch,et al.  A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. , 2014, European journal of cancer.

[28]  A. Lluch,et al.  An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer. , 2013, Breast.

[29]  J. Bergh,et al.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Pusztai,et al.  Stability of estrogen receptor status in breast carcinoma , 2011, Cancer.

[31]  A. Thompson,et al.  Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.

[32]  A. Vincent-Salomon,et al.  [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. , 2010 .

[33]  F. Penault-llorca,et al.  Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France , 2010 .

[34]  Donald L. Miller,et al.  Quality improvement guidelines for percutaneous needle biopsy. , 2010, Journal of vascular and interventional radiology : JVIR.

[35]  Consuelo Alvarez,et al.  Immunohistochemically determined estrogen receptor phenotype remains stable in recurrent and metastatic breast cancer. , 2008, American journal of clinical pathology.

[36]  Ian O Ellis,et al.  Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Winer,et al.  Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. , 2007, Breast.

[38]  Thomas Rüdiger,et al.  Quality Assurance in Immunohistochemistry: Results of an Interlaboratory Trial Involving 172 Pathologists , 2002, The American journal of surgical pathology.

[39]  D. Barnes,et al.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems , 2000, Journal of clinical pathology.

[40]  A. Vincent-Salomon,et al.  [Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]. , 2014, Annales de pathologie.

[41]  V. Valero,et al.  Stability of estrogen receptor status in breast carcinoma: A comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy , 2011 .

[42]  A. Vincent-Salomon,et al.  [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. , 2010, Annales de pathologie.

[43]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[44]  Robert C. Wolpert,et al.  A Review of the , 1985 .